RxDoctor Payments Data

Monica Thoms, MD

Ophthalmology · Arlington Heights, ILNPI 1922027606

Payments from drug & device makers

$3,228in general payments, 2019–2025

Across 117 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$720
  • Alcon$316
  • Biotissue Holdings Inc.$305
  • Regeneron Healthcare Solutions, Inc.$303
  • Bausch & Lomb Americas Inc.$239
  • Aerie Pharmaceuticals, Inc.$217
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,16598%
  • Education$181%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,228 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$338,969
Medicare patients
1,327
Services billed
4,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost77$50,294
RestasisCyclosporine16$29,911
XiidraLifitegrast13$13,598
Cyclosporine17$9,123
Latanoprost636$8,571
Travoprost37$6,704
RocklatanNetarsudil Mesylat/Latanoprost11$5,497
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$4,062
Timolol Maleate234$2,860
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha117$1,103
Pilocarpine Hcl12$952
Brimonidine Tartrate49$753
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$592
ErythromycinErythromycin Base33$325
Carteolol Hcl14$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$720$80,20593 claims
Bausch & Lomb Americas Inc.Xiidra$239$13,59813 claims
Aerie Pharmaceuticals, Inc.Rocklatan$217$5,49711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →